Bioxytran News and Resources

Bioxytran, Inc., a clinical-stage biotechnology company focusing on therapies for viral diseases and fibrotic conditions, has announced a $1.6 million common stock purchase agreement with TRITON FUNDS LP. The funds will be used to pay down existing debt, advance pre-clinical